OUTCOMES OF SUBSEQUENT TREATMENT AFTER ATEZOLIZUMAB–BEVACIZUMAB FOR HEPATOCELLULAR CARCINOMA. YHCĐ. 2026;67(10). doi:10.52163/yhc.v67i10.6872